Our fair value estimate for Adyen is EUR 1,950 and implies a 2024 enterprise value/EBITDA ratio of 36, which reflects the very strong growth rates we expect from Adyen. We reach our midcycle forecast ...
Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.